MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

13 Aug 2025 Evaluate
The revenue slipped marginally during the June 2025 quarter. A decline of about Rs. 166.99 millions was observed as compared to Rs. 170.45 millions during the corresponding quarter last year.Good  Net Profit growth of 34.34% reported above the corresponding previous quarter figure of Rs. 1.66 millions to Rs. 2.23 millioins.Operating profit for the quarter ended June 2025 rose to 5.42 millions as compared to 4.51 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 166.99 170.45 -2.03 166.99 170.45 -2.03 671.92 672.81 -0.13
Other Income 0.18 0.45 -60.00 0.18 0.45 -60.00 1.68 4.21 -60.10
PBIDT 5.42 4.51 20.18 5.42 4.51 20.18 29.30 27.18 7.80
Interest 0.26 0.21 23.81 0.26 0.21 23.81 1.03 0.63 63.49
PBDT 5.16 4.30 20.00 5.16 4.30 20.00 28.27 26.55 6.48
Depreciation 1.78 1.59 11.95 1.78 1.59 11.95 6.71 5.83 15.09
PBT 3.38 2.71 24.72 3.38 2.71 24.72 21.56 20.72 4.05
TAX 1.15 1.05 9.52 1.15 1.05 9.52 6.07 6.12 -0.82
Deferred Tax 0.06 0.29 -79.31 0.06 0.29 -79.31 0.18 0.25 -28.00
PAT 2.23 1.66 34.34 2.23 1.66 34.34 15.49 14.60 6.10
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 96.61 0.00
PBIDTM(%) 3.25 2.65 22.67 3.25 2.65 22.67 4.36 4.04 7.94
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..